BDRX
vs
S&P 500
BDRX
S&P 500
Over the past 12 months, BDRX has underperformed S&P 500, delivering a return of -90% compared to the S&P 500's +14% growth.
Stocks Performance
BDRX vs S&P 500
Performance Gap
BDRX vs S&P 500
Performance By Year
BDRX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Biodexa Pharmaceuticals PLC
Glance View
Biodexa Pharmaceuticals PLC is a GB-based company operating in Biotechnology industry. The company is headquartered in Abingdon, Oxfordshire and currently employs 27 full-time employees. The company went IPO on 2014-12-08. Biodexa Pharmaceuticals PLC is a United Kingdom-based drug delivery technology company. The firm is focused on improving the bio-delivery and bio-distribution of medicines. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. Biodexa Pharmaceuticals Q-Sphera technology focuses on long acting injectables using proprietary 3D printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. The company has a pipeline of approximately eight earlier stage programs, MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma), MTX110 (Glioblastoma), MTX114 (Psoriasis), MTD211 (Schizophrenia, MDD) and others.
